risk

New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk

Harvard Medical School Contributing Editor Atherosclerosis is the fundamental process in coronary artery disease, stroke, and many other vascular diseases. It is responsible for more than half of the disease burden of the United States, with an annual cost of over $100 billion. This includes over 1.5 million my...

Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent

Results Highlighted in Oral Presentation at International Symposiumof Thrombosis and Haemostasis GENEVA, July 10, 2007 /PRNewswire-FirstCall/ -- BaxterHealthcare Corporation today announced the presentation of findingsfrom the ADAPT (Analysis of Data from ADVATE(R) Prospective Trials)study program database showing a statistically significantrelationship between the duration of time spent...

International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis

- ENDORSE Global Findings Highlight the Need to UrgentlyImplement Hospital-Wide Strategies to Optimize VTE Management:Systematically Assess Patient Risk for VTE and Provide Appropriateprophylaxis to Prevent VTE Venous thromboembolism (VTE) risk is high among hospitalpatients and most of these at-risk patients are not pro...

New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility

EXCLAIM is the First International Study to Show That ExtendedThromboprophylaxis Reduces VTE Risk in Acutely-ill Medical PatientsWith a Statistically Significant 44% PARIS, July 8, 2007 /PRNewswire-FirstCall/ --Sanofi-aventisannounced today the results of the EXCLAIM (EXtended CLinicalprophylaxis in Acutely Ill Medical patients) study, which showedthe benefit of extended prophylaxi...

Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia

ROCHESTER, Minn., July 2, 2007-Women with at least three sites ofcellular atypia in breast tissue are nearly eight times more likelythan average women to develop breast cancer, according to findingsof a Mayo Clinic Cancer Center led study of women with atypicalhyperplasia. The findings are published in the July 1 issue of theJournal of Clinical Oncology. Several previous studies have show...

Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke

CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - Pfizer announced todaythat Lipitor (atorvastatin calcium) Tablets 80 mg reduced the riskof stroke, coronary heart disease events and major coronary eventsin type 2 diabetes patients who had no known coronary heart diseasebut who had experienced a recent stroke or mini-stroke, comparedwith placebo. The results are from a new analysis of the landmarkSt...

Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes

- BYETTA also Showed Sustained Improvements in Blood GlucoseControl and Progressive Weight Loss - CHICAGO, June 23, 2007 /PRNewswire-FirstCall/ -- AmylinPharmaceuticals, Inc. and Eli Lilly and Company today announcedresults from a study that showed BYETTA(R) (exenatide) injectionsustained improvements in blood sugar levels and progressive weightloss through three and a half years of thera...

Treating Heart Disease Risk Factors May Slow Alzheimer's Disease Progression

- Late Life Weight Loss and "Motivational Reserve" May Also AffectAlzheimer's Risk - WASHINGTON, June 10, 2007 /PRNewswire-USNewswire/ -- A new studysuggests that treating risk factors for heart disease and stroke,such as high blood pressure and diabetes, may slow the progressionof Alzheimer's disease, according to research reported today at the2nd Alzheimer's Association International Co...

Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death

"Patients and physicians should find these data reassuring" PHILADELPHIA, June 05, 2007 /PRNewswire-FirstCall/ --GlaxoSmithKline said today that findings from an interim analysisof RECORD (Rosiglitazone Evaluated for Cardiac Outcomes andRegulation of glycemia in Diabetes), a prospective clinical trialdesigned specifically to determine cardiovascular outcomes in morethan 4,400 patients wit...

New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel

22 US Oncology Affiliated Physicians Participate in ASCOProceedings HOUSTON, June 04, 2007 /PRNewswire/ -- A leading cancerresearcher affiliated with the US Oncology Research Networkpresented findings from a randomized, multicenter phase III trialthat compared the disease-free survival (DFS) obtained with tworegimens of adjuvant therapy for patients with high-risk breastcancer. Th...

Waismann Method Survey Reveals Dependency Risk for People Using Suboxone

BEVERLY HILLS, Calif.--(BUSINESS WIRE)--May 31, 2007 - The WaismannMethod today announced findings from an online survey of Suboxoneusers, indicating that 66 percent of individuals currently takingSuboxone, also known as Subutex or Buprenorphine, believe theycannot stop taking the drug without assistance, indicating aphysical dependency. Suboxone is often prescribed to treatdependency to op...

New Research Confirms the Benefit of Extended-Release Dipyridamole Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk Patients

Aggrenox® (Asasantin® Retard) considered by many asfirst-line in secondary stroke prevention INGELHEIM, Germany, 31 May 2007 - New data presented today at the16th European Stroke Conference in Glasgow confirm that therapywith dipyridamole plus ASA (extended-release dipyridamole plus ASAis marketed as Aggrenox® or Asasantin® Retard) is superiorto ASA* alone in...

Antidepressant Use May Boost Fracture Risk, From Harvard Women's Health Watch

BOSTON, May 29, 2007 /PRNewswire-USNewswire/ -- Evidence isaccumulating that depression is a risk factor for osteoporosis,reports the June 2007 issue of Harvard Women's Health Watch. Arecent study found that people ages 50 and over who regularly tookantidepressants called selective serotonin reuptake inhibitors(SSRIs) had double the rate of fractures as people not using suchmedications....

Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer

ANAHEIM, Calif.--(BUSINESS WIRE)--May 21, 2007 - Antigenics Inc.(NASDAQ: AGEN) today announced additional follow-up data on thecompany's Phase 3 investigational therapeutic cancer vaccineOncophage(R) (vitespen). The end-of-study results, which reflect anadditional 17 months' data collection, showed that in a substantialsubset of patients (n = 362) at intermediate risk for diseaserecurrence,...

Researchers Identify New Genetic Risk Factors for Type 2 Diabetes

Landmark Study Shows At Least 10 Genetic Variants Are AssociatedWith Adult Onset Diabetes BETHESDA, Md., April 26, 2007 – In the mostcomprehensive look at genetic risk factors for type 2 diabetes todate, a U.S.-Finnish team, working in close collaboration with twoother groups, has identified at least four new genetic variantsassociated with increased risk of diabetes and conf...

New Data Show Xenical Significantly Reduces Cardiovascular Risk and More Than Doubles Weight Loss Achieved in Overweight and Obese People

BUDAPEST, April 24 /CNW/ - The weight loss medication Xenical(orlistat 120mg) significantly reduces weight and improvescardiovascular risk factors such as blood pressure, glycaemiccontrol and lipid profile in overweight and obese people with type2 diabetes and hypertension, according to a study analysispresented at the European Congress on Obesity (ECO), Budapest,Hungary.(1) Th...

The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke

Risk of Having a Venous ThromboEmbolism (VTE) is Reduced by aSignificant 43% in Acute Ischemic Stroke Patients Treated WithClexane(R) / Lovenox(R) BRIDGEWATER, N.J., April 20, 2007 /PRNewswire-FirstCall/ --Sanofi-aventis announced the publication of the PREVAIL (Preventionof VTE after Acute Ischemic Stroke with LMWH Enoxaparin) trial inthe April 21st issue of The Lancet. The results of th...

Researchers Discover a Common Variation in a Gene Segment that Increases the Risk for Prostate Cancer

BETHESDA, Md., April 1, 2007--Researchers report that avariation in a portion of DNA strongly predicts prostate cancerrisk and that this common variation may be responsible for up to 20percent of prostate cancer cases in white men in the United States.The research was conducted by investigators from the NationalCancer Institute (NCI), part of the National Institutes of Health,and their p...

ACC Presentation Indicates Interleukin-1 Gene Variants Determine Increased Risk for Coronary Artery Disease from Oxidized Phospholipids

WALTHAM, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - InterleukinGenetics, Inc. (AMEX:ILI) and collaborators at the University ofCalifornia San Diego today reported at the American College ofCardiology annual meeting that associations between coronary arterydisease (CAD) and both oxidized phospholipids (OxPL) and Lp(a)levels appear to be dependent on pro-inflammatory variants of theinterleukin-1...

Diabetes Linked to Higher Parkinson's Risk

Studies Also Show Eating Soy Nuts May Reduce Inflammation AfterMenopause; Weight-Loss Surgery Improves Beta Cell Function, ReducesInsulin Resistance ALEXANDRIA, Va., March 28, 2007 /PRNewswire/ -- People who havetype 2 diabetes are more likely to develop Parkinson's disease asthey age, though researchers are uncertain what accounts for thelink between the two diseases, according to a new...

Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients

NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Pfizer announced todaythat Lipitor(R) (atorvastatin calcium) Tablets 10 mg provided asignificant 61 percent reduction in stroke in patients with type 2diabetes and metabolic syndrome but without heart disease. In aseparate study, patients who had suffered a recurrent stroke ormini-stroke during the trial had a significant 53 percent reductionin t...

Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery

Largest Randomized Safety Program of Intravenous Antihypertensivesto Date Presented at ACC Scientific Sessions NEW ORLEANS, March 27, 2007 /PRNewswire-FirstCall/ -- Findingsfrom ECLIPSE**, the largest safety program comparing intravenousantihypertensive therapies, show that improved control ofperioperative hypertension -- a potentially harmful elevation inblood pressure just before, durin...

Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke

EXACT and CAPTURE 2 Findings Suggest Improved Outcomes in CarotidArtery Stenting ABBOTT PARK, Ill., March 26, 2007 /PRNewswire-FirstCall/ --Positive 30-day results from two Abbott studies confirm thatcarotid stenting can be performed with positive results byphysicians with a variety of background experience in real-world(non-clinical trial) settings in patients who are not favorablecandi...

Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2 Predicts Heart Disease Risk in Metabolic Syndrome Patients

NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Study results showthat elevated lipoprotein-associated phospholipase A2 (Lp-PLA2), acardiovascular-specific inflammatory enzyme associated withunstable plaque that can lead to heart attack and stroke, isespecially predictive of heart disease risk in patients with themetabolic syndrome--a serious medical condition that affects nearly50 million Ame...

REACH Registry Demonstrates That Multiple Arterial Disease Locations Sharply Increase the Risk of Major CV Events in Outpatients With Atherothrombosis

- The Reduction of Atherothrombosis for Continued Health(REACH) PARIS, March 20, 2007 /PRNewswire/ --The REACH Registry 1-yearresults paper published today in the Journal of the AmericanMedical Association (JAMA) show that outpatients withatherothrombosis have a surprisingly high risk of death or majorcardiovascular illness, especially if more than...

DVT Awareness Survey Findings for Respondents in High-Risk Groups: Obese Individuals

WASHINGTON, March 15, 2007 /PRNewswire/ -- Up to two millionAmericans are affected each year by DVT, with up to 600,000hospitalized. Its primary complication, pulmonary embolism (PE),claims up to 300,000 lives annually -- more than breast cancer andAIDS combined. The Coalition to Prevent Deep-Vein Thrombosis (DVT) recentlysponsored an online survey of a nationally representative sa...

Framingham Study Shows Parents Who Live Long Pass On Lower Risk of Cardiovascular Disease

BETHESDA, Md., March 13, 2007--New evidence suggests that if youcould choose your parents, you could reduce your risk ofcardiovascular disease. Researchers from the long-standingFramingham Heart Study (FHS), a program of the National Heart,Lung, and Blood Institute (NHLBI) of the National Institutes ofHealth, report that people whose parents live longer were morelikely to avoid developing h...